THE INTRATHECAL USE OF PRONTOSIL SOLUBLE

Publisher Website
Google Scholar
Abstract
Since the introduction of the original prontosil by Domagk1as a therapeutic agent against hemolytic streptococci in mice, its two derivatives prontosil soluble and sulfanilamide have been extensively used against a variety of infections in man. Experimental evidence by Rosenthal,2by Cooper, Gross and Mellon3and by Cooper and Gross4show that sulfanilamide has distinctly therapeutic properties in rats and mice infected with the type III pneumococcus. Heintzelman, Hadley and Mellon5reported a small series of nineteen cases of type III pneumococcus lobar pneumonia, which carries a high mortality in the Pittsburgh area. Of nine patients who received sulfanilamide, seven lived and two died, while of the remaining untreated patients eight died and two recovered. At the Meadowbrook Hospital6a crisis was induced by sulfanilamide twenty-four hours after onset of a type III lobar pneumonia, which was contrary to our experience with the disease

This publication has 0 references indexed in Scilit: